<DOC>
	<DOCNO>NCT01496365</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability effectiveness DS-5565 compare placebo ( inactive substance ) pregabalin diabetic subject DPN .</brief_summary>
	<brief_title>Treatment Neuropathic Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>Diabetic peripheral neuropathy ( DPN ) affect 50 % patient diabetes least 25 year . Up 26 % patient DPN experience neuropathic pain . DPN pain contributes sleep disorder , depression , anxiety , together may impact patient 's well-being quality life . There currently several drug use treat painful DPN . For example , Lyrica® ( pregabalin ) approve United States Food Drug Administration ( FDA ) treat neuropathic pain associate DPN commonly prescribe . The dosage FDA-approved drug limit side-effects dizziness , sleepiness , weight gain swell hand , leg , foot . As result , many patient suffer DPN pain get satisfactory pain relief .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Age &gt; 18 year age 2 . Able give inform consent willing comply schedule visit , treatment plan , laboratory test , trial procedure 3 . Type 1 type 2 diabetes hemoglobin A1c ( HbA1c ) ≤ 10 % Screening stable antidiabetic medication regimen least 30 day prior Screening ( insulin therapy acceptable ) 4 . Painful distal symmetrical sensorimotor polyneuropathy ( per American Society Pain Educators guideline ) diagnose least 6 month , base neurological history and/or examination ; diagnosis include absent reduce deep tendon reflex ankles 5 . At Screening , pain score ≥ 40 mm SFMPQ VAS 6 . At Randomization , pain score ≥ 40 mm SFMPQ VAS ADPS ≥ 4 11point NRS , latter calculate minimum 4 pain rating daily diary obtain 1week Baseline Period ( prior randomization ) 7 . Creatinine clearance &gt; 60 mL/min ( estimate use CockcroftGault equation ) 8 . Antidiabetic medication anticipate remain stable constant study period 9 . Women child bear potential ( WOCBP ) must use adequate method contraception detail protocol avoid pregnancy study 4 week study completion 1 . Diagnosis mononeuropathy 2 . Use concomitant medication may confound assessment efficacy and/or safety ( see Section 5.2 ) 3 . Major psychiatric disorder 4 . Have malignancy basal cell carcinoma within past 2 year 5 . At Visit 1 , white blood cell count &lt; 2500/mm3 , neutrophil count &lt; 1500/mm3 , platelet count &lt; 100 x 103/mm3 6 . Clinically significant unstable diabetes mellitus , unstable hepatic , respiratory , hematologic illness , unstable cardiovascular disease ( include myocardial infarction 3 month prior Visit 1 ) , symptomatic peripheral vascular disease 7 . Clinically significant finding Screening ECG 8 . History pernicious anemia , untreated hypothyroidism , chronic hepatitis B , hepatitis B within past 3 month , human immunodeficiency virus infection 9 . Amputations body part toe 10 . Prior therapeutic failure pregabalin gabapentin ( consider unresponsive intolerant treatment ) ; therapeutic failure implies lack efficacy follow full titration effective dos ( eg , 300 mg/day pregabalin ) 11 . Known hypersensitivity pregabalin gabapentin 12 . Requirement concomitant anticonvulsant antidepressant therapy , exception stable dos SSRIs 13 . Neurologic disorder unrelated DPN may confound assessment pain associate DPN 14 . Skin condition could alter sensation 15 . Other source pain may confound assessment selfevaluation pain due DPN 16 . Abuse prescription medication , street drug alcohol ( include alcohol dependence ) within last 1 year 17 . Current enrollment another investigational study , participation another investigational study past 30 day , current recent use investigational drug 18 . Pregnancy ( base lab test result ) breast feed 19 . Laboratory value exceed limit list Table 4.1 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Keywords : pain , diabetes , neuropathy</keyword>
</DOC>